Syrleno

Syrleno (Everolimus) is an oral medication used to manage certain types of tumors and organ transplant rejection. It belongs to the class of mTOR inhibitors, helping regulate cell growth. This product is manufactured in the EU and intended for oral administration. Always follow healthcare provider guidance when using Syrleno.

Everolimus, the active ingredient in Syrleno, is prescribed to treat specific cancers like pancreatic neuroendocrine tumors and advanced kidney cancer. It is also used to prevent organ transplant rejection in kidney and heart transplant patients. This medication works by inhibiting mTOR, a protein involved in cell growth and proliferation. Patients often ask, 'what is Everolimus used for' due to its role in managing serious conditions.

Syrleno (Everolimus) may help slow the progression of certain cancers or reduce the risk of organ rejection after a transplant. Some patients report improved quality of life while taking this medication. Common effects include changes in appetite or mild gastrointestinal discomfort. Individual responses to Everolimus can vary based on medical history and concurrent treatments.

Syrleno should be handled with care, especially by individuals with a history of infections or liver problems. Pregnant or breastfeeding individuals should avoid this medication unless directed by a healthcare provider. Regular blood tests may be required to monitor its effects. Always store Syrleno in a cool, dry place away from direct sunlight.

Everolimus can interact with a variety of medications, including certain antibiotics, antifungals, and immunosuppressants. Grapefruit and grapefruit juice may also affect how Everolimus works in the body. Patients should inform their healthcare provider about all medications and supplements they are taking. Alcohol use may increase the risk of side effects and should be discussed with a doctor.